Connor, Clark & Lunn Investment Management (CC&L)’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $660K | Sell |
3,113
-4,066
| -57% | -$798K | ﹤0.01% | 1310 |
|
|
2026
Q1 | $1.41M | Buy |
7,179
+4,809
| +203% | +$934K | ﹤0.01% | 1062 |
|
|
2025
Q4 | $411K | Buy |
+2,370
| New | +$432K | ﹤0.01% | 1344 |
|
|
2025
Q3 | – | Sell |
-28,373
| Closed | -$5.1M | – | 1540 |
|
|
2025
Q2 | $5.1M | Buy |
+28,373
| New | +$4.93M | 0.02% | 567 |
|
|
2024
Q2 | – | Sell |
-7,078
| Closed | -$942K | – | 1452 |
|
|
2024
Q1 | $942K | Sell |
7,078
-1,268
| -15% | -$165K | ﹤0.01% | 906 |
|
|
2023
Q4 | $1.15M | Sell |
8,346
-15,783
| -65% | -$2.07M | 0.01% | 824 |
|
|
2023
Q3 | $2.94M | Buy |
24,129
+11,145
| +86% | +$1.48M | 0.02% | 516 |
|
|
2023
Q2 | $1.83M | Buy |
12,984
+3,106
| +31% | +$428K | 0.01% | 626 |
|
|
2023
Q1 | $1.4M | Buy |
9,878
+4,140
| +72% | +$592K | 0.01% | 638 |
|
|
2022
Q4 | $898K | Sell |
5,738
-68
| -1% | -$9.77K | 0.01% | 732 |
|
|
2022
Q3 | $712K | Buy |
5,806
+9
| +0.2% | +$1.19K | ﹤0.01% | 728 |
|
|
2022
Q2 | $771K | Buy |
5,797
+2,423
| +72% | +$330K | ﹤0.01% | 679 |
|
|
2022
Q1 | $462K | Sell |
3,374
-20,228
| -86% | -$2.82M | ﹤0.01% | 794 |
|
|
2021
Q4 | $4.08M | Buy |
23,602
+1,300
| +6% | +$198K | 0.02% | 370 |
|
|
2021
Q3 | $3.24M | Buy |
+22,302
| New | +$3.26M | 0.02% | 429 |
|
|
2021
Q2 | – | Sell |
-14,197
| Closed | -$1.82M | – | 999 |
|
|
2021
Q1 | $1.82M | Buy |
14,197
+1,336
| +10% | +$165K | 0.01% | 578 |
|
|
2020
Q4 | $1.53M | Sell |
12,861
-20,089
| -61% | -$2.45M | 0.01% | 568 |
|
|
2020
Q3 | $3.77M | Sell |
32,950
-16,802
| -34% | -$1.99M | 0.03% | 357 |
|
|
2020
Q2 | $5.67M | Buy |
+49,752
| New | +$5.28M | 0.04% | 272 |
|
|
2018
Q3 | – | Sell |
-2,125
| Closed | -$234K | – | 964 |
|
|
2018
Q2 | $234K | Buy |
+2,125
| New | +$221K | ﹤0.01% | 936 |
|
|
2017
Q1 | – | Sell |
-5,700
| Closed | -$524K | – | 928 |
|
|
2016
Q4 | $524K | Buy |
+5,700
| New | +$491K | ﹤0.01% | 597 |
|
|
2016
Q2 | – | Sell |
-13,861
| Closed | -$990K | – | 882 |
|
|
2016
Q1 | $990K | Sell |
13,861
-18,800
| -58% | -$1.26M | 0.01% | 457 |
|
|
2015
Q4 | $2.32M | Sell |
32,661
-41,112
| -56% | -$2.76M | 0.02% | 308 |
|
|
2015
Q3 | $4.54M | Buy |
73,773
+53,312
| +261% | +$3.73M | 0.04% | 212 |
|
|
2015
Q2 | $1.48M | Sell |
20,461
-7,900
| -28% | -$583K | 0.01% | 281 |
|
|
2015
Q1 | $2.18M | Sell |
28,361
-6,400
| -18% | -$458K | 0.02% | 221 |
|
|
2014
Q4 | $2.33M | Sell |
34,761
-68,400
| -66% | -$4.32M | 0.02% | 212 |
|
|
2014
Q3 | $6.26M | Buy |
103,161
+17,700
| +21% | +$1.09M | 0.05% | 125 |
|
|
2014
Q2 | $5.34M | Buy |
85,461
+78,100
| +1,061% | +$4.57M | 0.04% | 146 |
|
|
2014
Q1 | $471K | Sell |
7,361
-6,400
| -47% | -$343K | ﹤0.01% | 492 |
|
|
2013
Q4 | $783K | Buy |
+13,761
| New | +$816K | 0.01% | 419 |
|
Other funds holding DGX
EIG
Connor, Clark & Lunn Investment Management (CC&L)'s DGX Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) reduced its Quest Diagnostics (DGX) stake by 57% in Q2 2026, selling an estimated $798K and leaving 3,113 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #1310.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in DGX in Q4 2013 and has held it in 31 quarters since. The position peaked at $6.26M in Q3 2014. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) held 3,113 shares of Quest Diagnostics worth $660K as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) sold 4,066 Quest Diagnostics shares in Q2 2026, an estimated $798K.
- Quest Diagnostics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1310 holding.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Quest Diagnostics in Q4 2013 and has held it in 31 quarters since.
- Connor, Clark & Lunn Investment Management (CC&L)'s Quest Diagnostics position peaked at $6.26M in Q3 2014.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.